Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies
Shares of Obesity Drug Makers Lower, Proposal For Medicare Coverage Dropped
Trump Administration Declines Expansion of Coverage for Costly Obesity Drugs
RFK Jr. to Reinstate 20% of HHS Staff Laid off After DOGE Errors
Top Gap Ups and Downs on Thursday: UL, SHOP, NKE and More
FDA Inspections Office Facing Layoffs as Part of HHS Cuts
Artisan Global Opportunities Fund Trimmed Its Position in Novo Nordisk A/S (NVO)
Novo Nordisk Details Executive Management Changes
Novo Nordisk: Tania Sabroe, Head of People & Organisation, Will Also Head Global Communication
Novo Nordisk: Thilde Hummel Bogebjerg Promoted to Head Quality, IT & Environmental Affairs
Novo Nordisk: Ludovic Helfgott to Assume Responsibility for Pdt & Portfolio Strategy, Including Comml Strategy, Medical Affairs and Business Devt
Novo Nordisk: Executive VP of Comml Strategy & Corporate Affairs Camilla Sylvest to Leave Company
Novo Nordisk (0QIU) Gets a Sell From Jefferies
Top Gap Ups and Downs on Wednesday: DEO, FLUT, PHG and More
European stock markets fell as the market awaited Trump's tariff plan.
European stock markets fell as investors awaited an announcement from US President Trump regarding tariffs on trade partners. The Stoxx Europe 600 Index closed down 0.5%, with Medical Care stocks leading the decline. Novo-Nordisk A/S dropped 2.6%, contributing the most to the index's decline, after US company Hims & Hers Health Inc. announced an expansion of its weight loss drug supply. Retail and Travel & Leisure stocks outperformed. A cautious sentiment quietly entered the European market following the increase in the first quarter, as investors waited for Trump's so-called 'Liberation Day'. The tariffs are expected to take effect immediately after being announced later on Wednesday, and may even apply to.
CEO of Novo-Nordisk A/S: China's advantages have shifted towards high-quality innovation and will seek more Trade.
① The CEO of Novo Holdings, Kasim Kutai, stated on Wednesday that China's advantages have shifted from cost and efficiency to high-quality innovation. ② He indicated that after completing two investments in Innovative Drugs in China last year, Novo Holdings is seeking to engage in more biotechnology Trade in China. ③ Novo Holdings achieved a record investment return in 2024, adding 43 companies to its portfolio.
Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales
Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk
Novo Holdings Posts Record Total Income and Investment Returns of DKK 60 Billion (€8.0 Billion) in 2024, With the Investment Portfolio Delivering Above-benchmark Returns, Alongside Strong Growth at the Novo Group Companies
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?